Idiopathic interstitial pneumonia natural history, complications and prognosis
Idiopathic Interstitial Pneumonia Microchapters |
Differentiating Idiopathic interstitial pneumonia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Idiopathic interstitial pneumonia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Idiopathic interstitial pneumonia natural history, complications and prognosis |
FDA onIdiopathic interstitial pneumonia natural history, complications and prognosis |
CDC on Idiopathic interstitial pneumonia natural history, complications and prognosis |
Idiopathic interstitial pneumonia natural history, complications and prognosisin the news |
on Idiopathic interstitial pneumonia natural history, complications and prognosis |
Directions to Hospitals Treating Idiopathic interstitial pneumonia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Natural history and Complications
Biomarkers
The functional lung capacity, pulmonary functions and mortality have been linked to some biomarkers. This Table summarizes the findings of different research studies.
[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15].
Rapidly deteriorating lung function and higher mortality have been associated with high serum level of epithelial or macrophage-related proteins such as SP-A, SP-D, KL-6 (Krebs von den Lungen-6), CCL18 (chemokine ligand-18), and MMP-7 (matrix metalloproteinase-7) [4] [16] [17]
References
- ↑ Takahashi, H.; Fujishima, T.; Koba, H.; Murakami, S.; Kurokawa, K.; Shibuya, Y.; Shiratori, M.; Kuroki, Y.; Abe, S. (2000). "Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent". Am J Respir Crit Care Med. 162 (3 Pt 1): 1109–14. doi:10.1164/ajrccm.162.3.9910080. PMID 10988138. Unknown parameter
|month=
ignored (help) - ↑ Greene, KE.; King, TE.; Kuroki, Y.; Bucher-Bartelson, B.; Hunninghake, GW.; Newman, LS.; Nagae, H.; Mason, RJ. (2002). "Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis". Eur Respir J. 19 (3): 439–46. PMID 11936520. Unknown parameter
|month=
ignored (help) - ↑ Yokoyama, A.; Kondo, K.; Nakajima, M.; Matsushima, T.; Takahashi, T.; Nishimura, M.; Bando, M.; Sugiyama, Y.; Totani, Y. (2006). "Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis". Respirology. 11 (2): 164–8. doi:10.1111/j.1440-1843.2006.00834.x. PMID 16548901. Unknown parameter
|month=
ignored (help) - ↑ 4.0 4.1 Satoh, H.; Kurishima, K.; Ishikawa, H.; Ohtsuka, M. (2006). "Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases". J Intern Med. 260 (5): 429–34. doi:10.1111/j.1365-2796.2006.01704.x. PMID 17040248. Unknown parameter
|month=
ignored (help) - ↑ Takahashi, H.; Shiratori, M.; Kanai, A.; Chiba, H.; Kuroki, Y.; Abe, S. (2006). "Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D.". Respirology. 11 Suppl: S51–4. doi:10.1111/j.1440-1843.2006.00809.x. PMID 16423272. Unknown parameter
|month=
ignored (help) - ↑ Daniil, ZD.; Papageorgiou, E.; Koutsokera, A.; Kostikas, K.; Kiropoulos, T.; Papaioannou, AI.; Gourgoulianis, KI. (2008). "Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis". Pulm Pharmacol Ther. 21 (1): 26–31. doi:10.1016/j.pupt.2006.10.005. PMID 17161968.
- ↑ Rosas, IO.; Richards, TJ.; Konishi, K.; Zhang, Y.; Gibson, K.; Lokshin, AE.; Lindell, KO.; Cisneros, J.; Macdonald, SD. (2008). "MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis". PLoS Med. 5 (4): e93. doi:10.1371/journal.pmed.0050093. PMID 18447576. Unknown parameter
|month=
ignored (help) - ↑ Kinder, BW.; Brown, KK.; McCormack, FX.; Ix, JH.; Kervitsky, A.; Schwarz, MI.; King, TE. (2009). "Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis". Chest. 135 (6): 1557–63. doi:10.1378/chest.08-2209. PMID 19255294. Unknown parameter
|month=
ignored (help) - ↑ Barlo, NP.; van Moorsel, CH.; Ruven, HJ.; Zanen, P.; van den Bosch, JM.; Grutters, JC. (2009). "Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis". Sarcoidosis Vasc Diffuse Lung Dis. 26 (2): 155–61. PMID 20560296. Unknown parameter
|month=
ignored (help) - ↑ Prasse, A.; Pechkovsky, DV.; Toews, GB.; Schäfer, M.; Eggeling, S.; Ludwig, C.; Germann, M.; Kollert, F.; Zissel, G. (2007). "CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis". Arthritis Rheum. 56 (5): 1685–93. doi:10.1002/art.22559. PMID 17469163. Unknown parameter
|month=
ignored (help) - ↑ Gilani, SR.; Vuga, LJ.; Lindell, KO.; Gibson, KF.; Xue, J.; Kaminski, N.; Valentine, VG.; Lindsay, EK.; George, MP. (2010). "CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis". PLoS One. 5 (1): e8959. doi:10.1371/journal.pone.0008959. PMID 20126467.
- ↑ Richards, TJ.; Kaminski, N.; Baribaud, F.; Flavin, S.; Brodmerkel, C.; Horowitz, D.; Li, K.; Choi, J.; Vuga, LJ. (2012). "Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis". Am J Respir Crit Care Med. 185 (1): 67–76. doi:10.1164/rccm.201101-0058OC. PMID 22016448. Unknown parameter
|month=
ignored (help) - ↑ McKeown, S.; Richter, AG.; O'Kane, C.; McAuley, DF.; Thickett, DR. (2009). "MMP expression and abnormal lung permeability are important determinants of outcome in IPF". Eur Respir J. 33 (1): 77–84. doi:10.1183/09031936.00060708. PMID 18829682. Unknown parameter
|month=
ignored (help) - ↑ Shinoda, H.; Tasaka, S.; Fujishima, S.; Yamasawa, W.; Miyamoto, K.; Nakano, Y.; Kamata, H.; Hasegawa, N.; Ishizaka, A. (2009). "Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis". Respiration. 78 (3): 285–92. doi:10.1159/000207617. PMID 19270434.
- ↑ Richter, AG.; McKeown, S.; Rathinam, S.; Harper, L.; Rajesh, P.; McAuley, DF.; Heljasvaara, R.; Thickett, DR. (2009). "Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis". Thorax. 64 (2): 156–61. doi:10.1136/thx.2008.102814. PMID 18852160. Unknown parameter
|month=
ignored (help) - ↑ Prasse, A.; Probst, C.; Bargagli, E.; Zissel, G.; Toews, GB.; Flaherty, KR.; Olschewski, M.; Rottoli, P.; Müller-Quernheim, J. (2009). "Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis". Am J Respir Crit Care Med. 179 (8): 717–23. doi:10.1164/rccm.200808-1201OC. PMID 19179488. Unknown parameter
|month=
ignored (help) - ↑ Ishii, H.; Mukae, H.; Kadota, J.; Kaida, H.; Nagata, T.; Abe, K.; Matsukura, S.; Kohno, S. (2003). "High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia". Thorax. 58 (1): 52–7. PMID 12511721. Unknown parameter
|month=
ignored (help)